• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Mylan Pharmaceuticals Inc - Articles and news items


EMA accepts to review Mylan and Biocon’s cancer biosimilar

Industry news / 25 August 2016 / Niamh Louise Marriott, Digital Content Producer

Mylan and Biocon, who co-developed this proposed biosimilar, anticipate that this may be the first MAA for a trastuzumab biosimilar accepted by the EMA…


Phase 3 programme for revefenacin in COPD starts

Industry news / 14 September 2015 / Victoria White

The Phase 3 programme includes two replicate three-month efficacy studies and a single 12-month safety study…


Mylan commences offer to acquire Perrigo

Industry news / 14 September 2015 / Victoria White

Under the terms of the offer, Perrigo shareholders will receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share…


Mylan shareholders approve proposed acquisition of Perrigo

Industry news / 28 August 2015 / Victoria White

Mylan’s proposed acquisition of Perrigo received the approval of two-thirds of the votes cast by Mylan shareholders at an extraordinary general meeting…


ISS recommends Mylan shareholders vote “against” Perrigo bid

Industry news / 17 August 2015 / Victoria White

The ISS has recommended that Mylan shareholders vote “against” the unsolicited offer to acquire all of the outstanding shares of Perrigo…


Teva withdraws proposal to acquire Mylan

Industry news / 28 July 2015 / Victoria White

Following yesterday’s news that Teva is to acquire Allergan’s global generics business, Teva has withdrawn its cash and stock proposal to acquire Mylan…


Mylan and Dr Reddy’s launch Memantine hydrochloride tablets in the US

Industry news / 15 July 2015 / Victoria White

Both Mylan and Dr. Reddy’s have launched Memantine hydrochloride tablets USP, 5 mg and 10 mg, which is the generic version of Namenda Tablets, in the US…


Mylan launches Sirdupla in the UK for adult sufferers of asthma

Industry news / 8 June 2015 / Victoria White

Mylan has launched the first bioequivalent alternative to GlaxoSmithKline’s Seretide Evohaler under the brand name Sirdupla in the UK…


Teva completes acquisition of Auspex; continues pursuit of Mylan

Industry news / 6 May 2015 / Victoria White

Teva has acquired Auspex Pharmaceuticals through the successful tender offer for all of the outstanding Auspex shares at $101.00 per share…


Mylan rejects Teva’s $40.1 billion cash and stock offer

Industry news / 28 April 2015 / Victoria White

Mylan has announced that its Board of Directors has unanimously rejected the unsolicited expression of interest from Teva to acquire the Company…


Teva makes $40 billion offer for Mylan

Industry news / 22 April 2015 / Victoria White

Teva has announced their proposal to acquire all of the outstanding shares of Mylan in a transaction valued at $82.00 per Mylan share…


Teva announces favorable court ruling in AZILECT® patent infringement litigation against Mylan

Industry news, News / 23 September 2013 / Teva

The Court has upheld the validity of Teva’s patent. Teva anticipates the Court will enter Judgment that prevents Mylan from launching its generic version of Azilect® until Teva’s patent expires in 2017.


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +